Atezolizumab + Lenvatinib/Sorafenib for Liver Cancer
(IMbrave251 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a Phase III, open-label, multicenter, randomized, two-arm study designed to evaluate the efficacy and safety of atezolizumab plus either lenvatinib or sorafenib versus lenvatinib or sorafenib alone in participants with locally advanced or metastatic Hepatocellular Carcinoma (HCC) who have progressed on prior systemic treatment with atezolizumab plus bevacizumab combination.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is the combination of Atezolizumab and Lenvatinib/Sorafenib safe for liver cancer patients?
The safety of Atezolizumab combined with Lenvatinib or Sorafenib for liver cancer specifically isn't directly addressed in the available studies, but Atezolizumab combined with another drug, Bevacizumab, has been used safely in older patients with liver cancer, showing no adverse effects in some cases.12345
How is the drug combination of Atezolizumab, Lenvatinib, and Sorafenib unique for liver cancer?
The combination of Atezolizumab, Lenvatinib, and Sorafenib for liver cancer is unique because it explores the use of these drugs together, potentially offering a new approach compared to the standard first-line treatment of Atezolizumab plus Bevacizumab. This combination may provide an alternative for patients who do not respond well to existing treatments.12567
What data supports the effectiveness of the drug combination Atezolizumab, Lenvatinib, and Sorafenib for liver cancer?
Who Is on the Research Team?
Clinical Trials
Principal Investigator
Hoffmann-La Roche
Are You a Good Fit for This Trial?
This trial is for adults with advanced liver cancer who've seen their disease progress after treatment with Atezolizumab and Bevacizumab. They should have a good performance status, meaning they're able to carry out daily activities with minimal assistance. Patients must not have certain other cancers or brain metastases that are causing symptoms or require treatment.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive atezolizumab plus lenvatinib or sorafenib, or lenvatinib or sorafenib alone until unacceptable toxicity or loss of clinical benefit
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Atezolizumab
- Lenvatinib
- Sorafenib
Atezolizumab is already approved in United States, European Union for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Hoffmann-La Roche
Lead Sponsor
Dr. Levi Garraway
Hoffmann-La Roche
Chief Medical Officer since 2019
MD from the University of Basel
Dr. Thomas Schinecker
Hoffmann-La Roche
Chief Executive Officer since 2023
PhD in Molecular Biology from New York University